胺碘酮对心力衰竭并心房颤动病人的疗效观察

目的：就胺碘酮对心力衰竭并心房颤动病人的疗效观察进行探讨。方法选择我院2008年11月到2013年1月所收治的心力衰竭并心房颤动患者50例，随机将所有患者分为2组，分别是治疗组、对照组，。对照组采用常规治疗方法，而治疗组在此基础上增加静脉注射胺碘酮溶液及口服胺碘酮。结果治疗组有效率为96％，对照组有效率为82％，二者存在着较为明显的差异，具有统计学意义（P〈0.05）。与治疗前相比，两组患者在治疗后血压值都出现了较为明显的变化，都达到正常水平，存在着统计学意义（P〈0.05）；但两组之间差异不存在着统计学意义（P〉0.05）。两组患者在治疗后都没有出现肾功能、肝功能损害、恶性心律失常、不可耐受性低血压等严重不良反应。结论胺碘酮对心力衰竭并心房颤动病人的疗效较佳，安全有效，无较为严重的不良反应，可以作为首选治疗药物，值得推广应用。

Efficacy of amiodarone in heart failure patients with atrial fibrillation

Objective To investigate the efficacy of amiodarone in heart failure patients with atrial fibrillation. Methods Fifty heart failure patients with atrial fibrillation admitted to our hospital from November 2008 to January 2013 were randomly divided into treatment group and control group. The control group received routine treatment, while the treatment group was intravenously injected with amiodarone solution and orally given amiodarone in addition to the routine treatment. Results The treatment group had a significantly higher response rate than the control group （96% vs 82%, P 〈0.05）. After treatment, both groups showed significant improvements in blood pressure （P 〈0.05）, which all returned to normal, but there was no significant difference between the two groups （P 〉0.05）. No patients developed severe adverse reactions, such as renal function impairment, liver function impairment, malignant arrhythmia, and intolerable hypotension, after treatment. Conclusion Amiodarone has good efficacy and high safety and does not cause severe adverse reactions in heart failure patients with atrial fibrillation. This therapy can be used as the first choice of medication and holds promise for clinical application.